-- 根據週一提交給印度證券交易所的文件顯示，Jagsonpal Pharmaceuticals（NSE：JAGSNPHARM，BOM：507789）第四財季淨利從去年同期的6,580萬盧比躍升至8,760萬盧比。 截至3月31日的季度，每股收益從去年同期的0.98盧比增加到1.21盧比。 文件顯示，營業收入年增至6.42億盧比，高於去年同期的5.856億盧比。 公司董事會宣布，截至3月31日的財年，每股派息4盧比。
Related Articles
International
April Richmond Fed Manufacturing Index 3 Vs. Expected 1 Print, Prior 0
Australia
Sportradar Names Sameer Deen COO
Sportradar (SRAD) said Tuesday it has appointed Sameer Deen as chief operating officer, starting May 18.Deen was most recently the chief commercial officer and president at Entain, an international sports betting and gaming entertainment company, Sportradar said.Price: $12.80, Change: $-1.14, Percent Change: -8.18%
$SRAD
Research
Research Alert: Strong Execution, Softer Outlook: Record Margins Amid Mixed Signals
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Itron's Q1 2026 results beat consensus with revenue of $587M (vs. $572M estimate) despite a 3% decline and non-GAAP EPS of $1.49 (vs. $1.24 estimate), though down $0.03 Y/Y. Record adjusted gross margin expanded 490 bps to 40.7%, fueled by strong execution and projects ahead of schedule. We view these results as validating the business mix evolution, with Outcomes growing 22% to $96M and service revenues surging 30% across all segments, while the new Resiliency Solutions segment contributed $16M. Q2 guidance of $560M-$570M revenue and $1.25-$1.35 EPS came well below consensus of $606M/$1.46, requiring management clarity on project timing explanations. We believe the declining backlog (down 6% to $4.4B) coupled with Networked Solutions revenue declines represent a worrisome double headwind worth monitoring. However, our long-term thesis remains intact as we see the revenue shift toward AI-powered grid analytics as positive, supported by robust $79M free cash flow and accelerating demand in the Outcomes segment.
$ITRI